Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Reference33 articles.
1. AlMukdad S, Elewa H, Al-Badriyeh D. Economic evaluations of CYP2C19 genotype-guided antiplatelet therapy compared to the universal use of antiplatelets in patients with acute coronary syndrome: a systematic review. J Cardiovasc Pharmacol Ther. 2020;25(3):201–11. https://doi.org/10.1177/1074248420902298. (PMID: 32027168).
2. Bapatla N, Ramoutar UD, Sharma N, Ramoutar A, Ortega VL, Goorachan A, Haffizulla F. Cardiovascular disease in the Indo-Caribbean population: a scoping review. Cureus. 2021;13(6): e15375.
3. Chadee D, Seemungal T, Pinto LM, Pereira MC, Maharaj R, Teelucksingh S. Prevalence of self-reported diabetes, hypertension and heart disease in individuals seeking state funding in Trinidad and Tobago, West Indies. J Epidemiol Global Health. 2013;3(2):95–103.
4. Claassens DMF, van Dorst PWM, Vos GJA, Bergmeijer TO, Hermanides RS, van’t Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Postma MJ, Deneer VHM, Ten Berg JM, Boersma C. Cost effectiveness of a CYP2C19 genotype-guided strategy in patients with acute myocardial infarction: results from the POPular genetics trial. Am J Cardiovasc Drugs. 2022;22(2):195–206. https://doi.org/10.1007/s40256-021-00496-4. (PMID: 34490590).
5. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46(4):594–8.